Information Provided By: 
Fly News Breaks for January 13, 2020
LLY, NXTC
Jan 13, 2020 | 15:23 EDT
Piper Sandler analyst Edward Tenthoff notes that NextCure (NXTC) disclosed that Eli Lilly (LLY) is terminating an I-O discovery alliance based on the former's FIND-IO platform effective March 3rd. The analyst does not view this termination as a negative for NextCure's existing, wholly-owned antibodies NC318 and NC410 and is a buyer on weakness. Tenthoff adds that NextCure remains a top pick for 2020 ahead of additional NC318 data this year. He reiterates an Overweight rating and $87 price target on NextCure's shares.
News For NXTC;LLY From the Last 2 Days
There are no results for your query NXTC;LLY
